Want to see CNTN full AI Analyst Report?
Top Page
Canton Strategic Holdings
(NASDAQ:CNTN)
Select Model
Select Model
Rating:48Neutral
Price Target:
$2.00
▼(-10.31% Downside)
Action:Reiterated
Date:10/18/26
The score is held back primarily by weak fundamentals (deep and widening losses with ongoing cash burn) and a clearly bearish technical trend (price below all major moving averages with negative momentum). The main offsetting strength is a solid, low-leverage balance sheet with zero debt and substantial equity, but valuation remains unattractive because profitability is negative and no dividend support is provided.
Positive Factors
Debt-free capitalization
A debt-free balance sheet with substantial equity and assets gives Canton greater financial flexibility than a highly leveraged peer. This capitalization can help absorb operating volatility and preserve options for restructuring, investment, or other strategic actions over the coming quarters.
Negative Factors
Minimal revenue and deep losses
The very small revenue base does not currently support the scale of reported losses, indicating weak operating leverage and limited evidence of a self-sustaining commercial model. Persistently widening losses can erode capital and increase the importance of future execution or funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free capitalization
A debt-free balance sheet with substantial equity and assets gives Canton greater financial flexibility than a highly leveraged peer. This capitalization can help absorb operating volatility and preserve options for restructuring, investment, or other strategic actions over the coming quarters.
Read all positive factors
Canton Strategic Holdings (CNTN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$137.85M
Dividend YieldN/A
Average Volume (3M)875.07K
Price to Earnings (P/E)―
Beta (1Y)1.12
Revenue GrowthN/A
EPS Growth75.98%
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding79,681,360
10 Day Avg. Volume859,272
30 Day Avg. Volume875,069
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.24
Price to Sales (P/S)0.00
P/FCF Ratio-1.04
Enterprise Value/Market Cap4.17
Enterprise Value/Revenue383.94
Enterprise Value/Gross Profit383.94
Enterprise Value/Ebitda-7.75
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Canton Strategic Holdings Business Overview & Revenue Model
Company Description
Canton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas. The company is committed to promoting the institutional integration of blockchain technology and fos...
Canton Strategic Holdings Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -74.08M | -20.06M | -12.21M | 152.63K | -5.31M | -1.38M |
| Net Income | -98.12M | -35.92M | -12.20M | -9.32M | -8.47M | -2.21M |
Balance Sheet | ||||||
| Total Assets | 564.57M | 519.15M | 3.72M | 10.95M | 6.69M | 621.68K |
| Cash, Cash Equivalents and Short-Term Investments | 37.24M | 17.03M | 3.56M | 10.94M | 6.51M | 4.36K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.17M |
| Total Liabilities | 109.67M | 121.22M | 2.41M | 1.82M | 1.14M | 5.31M |
| Stockholders Equity | 454.90M | 397.93M | 1.31M | 9.13M | 5.54M | -4.68M |
Cash Flow | ||||||
| Free Cash Flow | -22.17M | -93.70M | -10.90M | -7.30M | -6.56M | -1.09M |
| Operating Cash Flow | -22.17M | -16.13M | -10.90M | -7.30M | -6.56M | -1.09M |
| Investing Cash Flow | -138.16M | -77.57M | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 195.91M | 107.17M | 3.53M | 11.72M | 13.06M | 898.75K |
Canton Strategic Holdings Technical Analysis
Negative
2.23
Price Trends
2.16
Negative
2.30
Negative
3.00
Negative
Market Momentum
-0.12
Positive
41.91
Neutral
34.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTN, the sentiment is Negative. The current price of 2.23 is above the 20-day moving average (MA) of 2.12, above the 50-day MA of 2.16, and below the 200-day MA of 3.00, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 41.91 is Neutral, neither overbought nor oversold. The STOCH value of 34.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CNTN.
Canton Strategic Holdings Risk Analysis
Canton Strategic Holdings disclosed 71 risk factors in its most recent earnings report. Canton Strategic Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Canton Strategic Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $137.85M | -1.23 | -29.54% | ― | ― | 75.98% | |
48 Neutral | $67.51M | -61.39 | -27.88% | ― | 6.65% | -136.61% | |
46 Neutral | $34.62M | -0.73 | -156.02% | ― | -95.74% | -23.18% | |
46 Neutral | $71.59M | -0.45 | -218.94% | ― | ― | ― | |
41 Neutral | $320.72M | -1.96 | -53.86% | ― | ― | -7.24% |
* Healthcare Sector Average
CNTN
Canton Strategic Holdings
1.86
-1.04
-35.86%
CRVO
CervoMed
2.24
-4.84
-68.36%
CSBR
Champions Oncology
4.76
-1.99
-29.48%
PTHS
Pelthos Therapeutics
19.59
-15.06
-43.46%
ARTV
Artiva Biotherapeutics, Inc.
6.20
1.36
28.10%
Canton Strategic Holdings Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A TransactionsRegulatory Filings and Compliance
Canton Strategic Completes Gravitas Divestiture, Refocuses Strategy
Neutral
Jul 23, 2026
On July 17, 2026, Canton Strategic Holdings completed the sale of all membership interests in Gravitas Life Sciences, its clinical-stage biotech subsidiary, to Gravitas Collective Corp., an entity affiliated with former company directors, followin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.